| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Guest Access | Sign In via User Name/Password
|
|
|
|||||||
Guest Access | Sign In via User Name/Password |
|||||||||
1 From the Research Institute for Diseases of the Chest, Faculty of Medicine, Kyushu University, Japan
2 From the National Minami-Fukuoka Chest Hospital, Japan
Objective: Thromboxane A2 (TXA2) is reported to induce bronchial hyperresponsiveness along with the well-documented bronchoconstrictor action on smooth muscles. We examined the effect of the TXA2 antagonist, BAY u3405, on bronchial hyperresponsiveness to methacholine (MCh) in asthmatics.
Patients: Twelve adult asthmatics were studied in a randomized, double-blind, placebo-controlled, crossover fashion.
Design: Following a 2-week run-in period, the subjects were administered 75 mg of BAY u3405 or placebo orally, twice a day for 2 weeks each in a crossover design, interposing a 2-week washout period. Bronchial hyperresponsiveness was measured by the astograph method. Briefly, the respiratory resistance (Rrs) was measured by the forced oscillation method during continuous inhalation of MCh in stepwise incremental concentrations, until Rrs reached twice the baseline value. Bronchial hyperrresponsiveness was evaluated as the minimum cumulative dose (Dmin) of MCh that induced an increase in Rrs. Dmin was calculated so that 1 U of Dmin equals to 1 min of inhalation of aerosol solution at 1.0 mg/mL during quiet breathing.
Results: Three subjects were withdrawn from the evaluation because they had asthmatic attacks or wheezing during the study. The Dmin value of 0.533 U (GSEM 1.675) after the BAY u3405 treatment was significantly greater than that of 0.135 U (GSEM 1.969) after the placebo treatment (p=0.0139). There were no safety concerns in either treatment group.
Conclusion: We conclude that BAY u3405 may be a useful drug for attenuating bronchial hyperresponsiveness in bronchial asthma.
Key Words: astograph • bronchial asthma • methacholine • thromboxane A2
Submitted on December 14, 1994
Accepted on September 27, 1995
This article has been cited by other articles:
|
|
 |
|
  A. Wohlsen, C. Martin, E. Vollmer, D. Branscheid, H. Magnussen, W-M. Becker, U. Lepp, and S. Uhlig The early allergic response in small airways of human precision-cut lung slices Eur. Respir. J., June 1, 2003; 21(6): 1024 - 1032. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Sugimoto, M. Shichijo, T. Iino, Y. Manabe, A. Watanabe, M. Shimazaki, F. Gantner, and K. B. Bacon An Orally Bioavailable Small Molecule Antagonist of CRTH2, Ramatroban (BAY u3405), Inhibits Prostaglandin D2-Induced Eosinophil Migration in Vitro J. Pharmacol. Exp. Ther., April 1, 2003; 305(1): 347 - 352. [Abstract] [Full Text]
|
|
|
|
|
|
H. Hirose, I. Aoki, T. Kimura, T. Fujikawa, T. Numazawa, K. Sasaki, A. Sato, T. Hasegawa, M. Nishikibe, M. Mitsuya, et al. Pharmacological Properties of (2R)-N-[1-(6-Aminopyridin-2-ylmethyl)piperidin-4-yl]-2-[(1R)-3,3-difluorocyclopentyl]-2- hydroxy-2-phenylacetamide: A Novel Muscarinic Antagonist with M2-Sparing Antagonistic Activity J. Pharmacol. Exp. Ther., April 12, 2001; 297(2): 790 - 797. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. Tamaoki, M. Kondo, J. Nakata, Y. Nagano, K. Isono, and A. Nagai Effect of a Thromboxane A2 Antagonist on Sputum Production and Its Physicochemical Properties in Patients With Mild to Moderate Asthma Chest, July 1, 2000; 118(1): 73 - 79. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Barnes, K. F. Chung, and C. P. Page Inflammatory Mediators of Asthma: An Update Pharmacol. Rev., December 1, 1998; 50(4): 515 - 596. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
